Publicaciones en las que colabora con Norberto Ortego Centeno (13)

2024

  1. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2022

  1. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

    Journal of Clinical Medicine, Vol. 11, Núm. 19

2021

  1. Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (Scientific Reports, (2021), 11, 1, (11510), 10.1038/s41598-021-91055-z)

    Scientific Reports

  2. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

  2. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

    Scientific Reports, Vol. 7

  3. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort

    Autoimmunity Reviews, Vol. 16, Núm. 8, pp. 796-802

2016

  1. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

2015

  1. Registry of the Spanish network for systemic sclerosis: Survival, prognostic factors, and causes of death

    Medicine (United States), Vol. 94, Núm. 43

2014

  1. Influence of the IL17A locus in giant cell arteritis susceptibility

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 9, pp. 1742-1745

2011

  1. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

    Arthritis Research and Therapy, Vol. 13, Núm. 4

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476